Last reviewed · How we verify
Placebo, Omeprazole or Rabeprazole, Clarithromycin
Omeprazole and Rabeprazole are proton pump inhibitors that reduce gastric acid secretion, while Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis.
Omeprazole and Rabeprazole are proton pump inhibitors that reduce gastric acid secretion, while Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. Used for Eradication of Helicobacter pylori in patients with peptic ulcer disease, Treatment of gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Placebo, Omeprazole or Rabeprazole, Clarithromycin |
|---|---|
| Also known as | Placebo |
| Sponsor | National Cancer Center, Korea |
| Drug class | Proton pump inhibitor, Macrolide antibiotic |
| Target | H+/K+ ATPase, 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal, Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
Omeprazole and Rabeprazole work by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, resulting in a decrease in gastric acid secretion. Clarithromycin, on the other hand, binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis and ultimately leading to bacterial cell death.
Approved indications
- Eradication of Helicobacter pylori in patients with peptic ulcer disease
- Treatment of gastroesophageal reflux disease (GERD)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Headache
- Dizziness
- Clarithromycin: QT interval prolongation
Key clinical trials
- Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD (PHASE3)
- Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: